Oscotec Inc. (KOSDAQ:039200)

Market Cap	1.99T +80.0%
Revenue (ttm)	99.84B +193.6%
Net Income	52.34B +5,871.6%
EPS	1,368.00 +5,868.9%
Shares Out	38.26M
PE Ratio	38.01
Forward PE	61.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	223,385
Average Volume	229,073
Open	53,000
Previous Close	53,500
Day's Range	51,600 - 53,500
52-Week Range	25,000 - 66,000
Beta	1.17
RSI	48.39
Earnings Date	May 12, 2026

About Oscotec

Oscotec Inc. operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses. It develops SKI-O-703, a SYK inhibitor that is in Phase 2 clinical trials to treat rheumatoid arthritis and idiopathic thrombocytopenic purpura; SKI-G-801, a selective FLT3/AXL inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia, as well as other solid tumors; and lazertinib, a 3rd generation EGFR inhibitor that is in Phase 3 clinical trials...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1998
• Employees: 53
• Stock Exchange: KOSDAQ
• Ticker Symbol: 039200

Financial Performance

In 2025, Oscotec's revenue was 99.84 billion, an increase of 193.58% compared to the previous year's 34.01 billion. Earnings were 52.34 billion, an increase of 5871.65%.